Search Results - "Djebbari, Faouzi"

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review by Eyre, Toby A, Djebbari, Faouzi, Kirkwood, Amy A, Collins, Graham P

“…Central nervous system (CNS) relapse of diffuse large B-cell lymphoma remains uncommon but catastrophic. The benefit of standalone intrathecal prophylaxis in…”
Get full text

A systematic review of non-standard dosing of oral anticancer therapies by Djebbari, Faouzi, Stoner, Nicola, Lavender, Verna Teresa

“…The use of oral systemic anticancer therapies (SACT) has increased and led to improved cancer survival outcomes, particularly with the introduction of small…”
Get full text

Clinical outcomes of bortezomib-based therapy in myeloma by Djebbari, Faouzi, Srinivasan, Anandagopal, Vallance, Grant, Moore, Sally, Kothari, Jaimal, Ramasamy, Karthik

“…Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed myeloma settings. Considerable differences exist in the usage…”
Get full text

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series by Djebbari, Faouzi, Poynton, Matt, Sangha, Gina, Anderson, Laura, Maddams, Rebecca, Eyre, Toby A., Vallance, Grant, Basu, Supratik, Ramasamy, Karthik

“…Objectives: Daratumumab is the first anti-CD38 monoclonal antibody (Mab) used to treat myeloma in the newly diagnosed setting and in the relapsed setting…”
Get full text

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients by Djebbari, Faouzi, Sharpley, Faye A, McLain-Smith, Susan, Vallance, Grant, Eyre, Toby A, Kothari, Jaimal, Moore, Sally, Ramasamy, Karthik

“…Treatment of transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM) requires a balance between disease control and maintaining quality of life…”
Get full text

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care by Djebbari, Faouzi, Panitsas, Fotios, Eyre, Toby A, Prodger, Catherine, Davies, Fearn, Burton, Kieran, Khera, Akhil, Vallance, Grant, Moore, Sally, Kothari, Jaimal, Peniket, Andy, Ramasamy, Karthik

Get full text

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients by Djebbari, Faouzi, Rampotas, Alexandros, Panitsas, Fotios, Lim, Wen Yuen, Lees, Charlotte, Tsagkaraki, Ismini, Gomes, Ana Rita, Prideaux, Steve, Chen, Lucia, Prodger, Catherine, Khera, Akhil, Gray, Nicola, Ellis, Lauren, Sangha, Gina, Eyre, Toby A, Moore, Sally, Kothari, Jaimal, Ramasamy, Karthik

“…The management of myeloma in the elderly is shifting its focus towards reducing the risk of under-treating fit patients and the risk of over-treating frail…”
Get full text

Treat or palliate: outcomes of very elderly myeloma patients by Panitsas, Fotios, Kothari, Jaimal, Vallance, Grant, Djebbari, Faouzi, Ferguson, Lisa, Sultanova, Manuela, Ramasamy, Karthik

Get full text

Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol by Djebbari, Faouzi, Stoner, Nicola, Lavender, Verna

“…Recent advances in cancer therapeutics have resulted in significantly improved overall survival and progression-free survival for patients. Targeted oral…”
Get full text

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study by Djebbari, Faouzi, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Firas, Al-Kaisi, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Eyre, Toby A., Bygrave, Ceri, Basu, Supratik, Ramasamy, Karthik

“…There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination…”
Get full text

Resource implications of bortezomib therapy in a large UK cohort: An evaluation study by Djebbari, Faouzi, Tatarczuch, Maciej, Panitsas, Fotios, Vallance, Grant, Sultanova, Manuela, Kothari, Jaimal, Ramasamy, Karthik, Peniket, Andy

“…Background Bortezomib is a cornerstone in the management of multiple myeloma. It remains an attractive treatment option because it is efficacious, reasonably…”
Get full text

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK‐Wide Real‐World Dataset by Djebbari, Faouzi, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Al‐Kaisi, Firas, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Bygrave, Ceri, Basu, Supratik, Ramasamy, Karthik

“…Real‐world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma patients have not…”
Get full text

Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID‐19 pandemic by Willan, John, King, Andrew J., Djebbari, Faouzi, Turner, Gareth D. H., Royston, Daniel J., Pavord, Sue, Collins, Graham P., Peniket, Andy

Get full text

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity by Djebbari, Faouzi, Kaji, Furqaan, Stanton, Louise, Collins, Graham P., Eyre, Toby A.

“…Background Follicular lymphoma (FL) patients (pts) receiving immunochemotherapy now have a median overall survival (OS) of 15-20 years (y). ~80% of pts…”
Get full text

Long term outcomes in monoclonal gammopathy of renal significance by Khera, Akhil, Panitsas, Fotios, Djebbari, Faouzi, Kimberger, Katja, Stern, Simon, Quinn, John, Rabin, Neil, Kothari, Jaimal, Alchi, Bassam, Haynes, Richard, Winearls, Christopher, Roberts, Ian, Ramasamy, Karthik

“…Summary Unlike AL amyloid and cast nephropathy, the long‐term outcomes of monoclonal gammopathy of renal significance (MGRS) patients with other renal…”
Get full text

Systematic Review of Non-Conventional Dosing of Oral Anticancer Therapies in Malignant Haematology by Djebbari, Faouzi, Stoner, Nicola, Lavender, Verna

“…Introduction Survival outcomes for patients with lymphoid, myeloid and plasma cell malignancies, have improved with the use of oral small molecule inhibitory…”
Get full text

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care by Djebbari, Faouzi, Panitsas, Fotios, Eyre, Toby A, Prodger, Catherine, Davies, Fearn, Burton, Kieran, Khera, Akhil, Vallance, Grant, Moore, Sally, Kothari, Jaimal, Peniket, Andy, Ramasamy, Karthik

Get full text

Optimising Therapeutic Outcomes of Patients with Haematological Malignancies (Multiple Myeloma) by Djebbari, Faouzi

“…Multiple myeloma (MM) is a haematological malignancy of plasma cells. It is caused by an uncontrolled proliferative behaviour of clonal B cells. Cancer…”
Get full text

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model by Djebbari, Faouzi, Rampotas, Alexandros, Panitsas, Fotios, Lim, Wen Yuen, Lees, Charlotte, Tsagkaraki, Ismini, Gomes, Ana Rita, Prideaux, Steve, Chen, Lucia, Prodger, Catherine, Khera, Akhil, Gray, Nicola, Ellis, Lauren, Sangha, Gina, Eyre, Toby A, Moore, Sally, Kothari, Jaimal, Ramasamy, Karthik

“…The management of myeloma in the elderly is shifting its focus towards reducing the risk of under-treating fit patients and the risk of over-treating frail…”
Get full text

Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience by Djebbari, Faouzi, Hubenov, Huben, Neelakantan, Pratap, Wolf, Julia, Offer, Mark, Khera, Akhil, Louka, Eleni, Vallance, Grant, Kothari, Jaimal, Moore, Sally, Ramasamy, Karthik

Get full text